IBL HealthCare Limited held a Corporate Briefing Session for FY2026, outlining its strategic refocus and financial performance. The company emphasized its commitment to the Nutrition and Medical & Surgical Disposables sectors while discontinuing non-aligned portfolios.
- Session conducted on November 2, 2026, covering company overview, financial highlights, future outlook, and Q&A.
- FY2026 net revenue reached PKR 4.61B, up 7% year-on-year, driven by a 15% increase in continuing business.
- Gross profit rose to PKR 1.64B, with a margin of 36%, reflecting improved product mix and pricing strategies.
- Profit before tax increased by 18% to PKR 401M, while profit after tax was PKR 220M, marking a 6% growth.
- The company is investing in marketing, with expenses up 17% to PKR 1.006B, aimed at enhancing brand presence in the Nutrition sector.
- Future outlook includes deepening focus on core verticals, new product launches, and continued investment in talent and training.
- Risks identified include FX exposure, import costs, and regulatory challenges, with a commitment to strong governance and risk management practices.